STAT

JUNE 12, 2024

This is Part 1 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. Prescription drug costs are remarkably higher in the United States than in other countries, so it’s no surprise that more than half of U.S.

Drug Pricing 336

Drug Pricing 336

STAT

SEPTEMBER 26, 2024

Biden administration officials have abandoned their own proposal to require drug companies to disclose the prices and research costs of drugs that are driving up spending in state Medicaid programs.

Drug Pricing 352

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 352

STAT

FEBRUARY 1, 2024

WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

Drug Pricing 324

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 324

STAT

SEPTEMBER 20, 2024

WASHINGTON — A federal appeals court ruled that three organizations, including the brand drug lobby PhRMA, can challenge Medicare’s drug price negotiation program in a lower court based in Texas. Continue to STAT+ to read the full story…

Drug Pricing 308

Drug Pricing 308

STAT

FEBRUARY 8, 2024

Bernie Sanders’ prescription drug pricing theater. WASHINGTON — Call it Sen. The hearing, featuring Merck CEO Robert Davis, Johnson and Johnson CEO Joaquin Duato, and Bristol Myers Squibb CEO Chris Boerner, was designed to draw public interest, and in that respect, it worked.

Drug Pricing 315

Drug Pricing 315

STAT

MAY 6, 2024

The changing landscape of drug pricing policy in the U.S. Drug policy changes are being influenced by perceptions of the value of novel medicines relative to their budgetary impacts, with some believing that many medicines may not be worth their cost, creating an important role for health technology assessments (HTA).

Drug Pricing 360

Drug Pricing 360

STAT

JULY 15, 2024

Medicare’s new guidelines cover how it will conduct the drug price negotiations authorized by the Inflation Reduction Act. It will also deter companies from doing research on existing medicines to create improved versions that are more effective and have fewer side effects.

Drug Pricing 309

Drug Pricing Hospitals 309

STAT

AUGUST 8, 2024

How will we know if the the government gets a good deal in the first round of drug pricing negotiations? ” STAT’s Washington Correspondent John Wilkerson joins us to discuss the first round of drug pricing negotiations under the Inflation Reduction Act, which will wrap up by September 1.

Drug Pricing 278

Drug Pricing Drug Development 278

STAT

AUGUST 15, 2024

Almost exactly two years ago, the Inflation Reduction Act was signed into law, allowing Medicare to negotiate drug prices for the first time. Today, the agency announced how much it lowered the costs for 10 drugs in the first year of negotiation.   Sign up  to get our Morning Rounds newsletter in your inbox.

Drug Pricing 285

Drug Pricing 285

STAT

FEBRUARY 8, 2024

LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor drugmakers are wanting to show their cards, at least publicly.

Drug Pricing 323

Drug Pricing Diabetes 323

STAT

OCTOBER 29, 2024

The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription drugs for millions of people with Medicare. The law laid out aggressive timelines for implementing the Medicare Drug Price Negotiation Program.

Drug Pricing 311

Drug Pricing 311

STAT

AUGUST 15, 2024

Are pharma companies still fearful of the Inflation Reduction Act? Will Lykos’ FDA rejection and recent publication retractions pull down the entire psychedelics industry? And what would you name a commercial psychotherapy treatment? We discuss all that and more on this week’s episode of “The Readout LOUD.”

Drug Pricing 278

Drug Pricing 278

STAT

NOVEMBER 2, 2023

WASHINGTON — A key Senate panel announced it will consider more policies to regulate pharmacy middlemen and ensure patients aren’t paying more than insurers do for medications. The package crafted by Senate Finance Chair Ron Wyden (D-Ore.) and Mike Crapo (R-Idaho) is slated to be marked up on Nov.

Packaging 354

Packaging Drug Pricing 354

STAT

MARCH 20, 2024

WASHINGTON — Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis from nonpartisan congressional budget experts.

Drug Pricing 343

Drug Pricing Diabetes 343

STAT

JANUARY 26, 2024

The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries.

Drug Pricing 334

Drug Pricing 334

STAT

DECEMBER 12, 2024

Top of the morning to you, and a fine one it is. Clear blue skies and chilly breezes are wafting across the Pharmalot campus, where the official mascots are snoozing after foraging for their breakfast. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation.

Drug Pricing 266

Drug Pricing Vaccines 266

STAT

JULY 5, 2024

WASHINGTON — A federal judge ruled against Boehringer Ingelheim’s challenge to the new Medicare drug price negotiation program, handing the pharmaceutical industry its latest in a string of legal losses. The company had argued before the U.S.

Drug Pricing 341

Drug Pricing Diabetes 341

STAT

JULY 22, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-so familiar routine of online meetings, phone calls, and deadlines has predictably returned. But what can you do? The world, such as it is, continues to spin.

Drug Pricing 317

Drug Pricing 317

STAT

JANUARY 22, 2024

So Sachs began reading about the drug, Xtandi , and found the annual list price at the time was about $156,000, or $427 a day, for men with commercial health insurance. In the fall of 2020, Robert Sachs was prescribed a medication to treat prostate cancer that had metastasized into some of his bones.

Drug Pricing 354

Drug Pricing 354

STAT

OCTOBER 17, 2024

Hello, and happy Thursday from Boston at the STAT Summit ! For those of you following along virtually, my co-author Sarah Owermohle is interviewing Atul Gawande, the assistant administrator of global health at USAID, this afternoon, and Bob Herman is interviewing former CMS administrator Don Berwick about the future of Medicare.

Drug Pricing 254

Drug Pricing 254

STAT

JULY 29, 2024

Through the creation of the Mark Cuban Cost Plus Drug Company (MCCPDC), Cuban aims to reduce drug prices and also drug shortages. Mark Cuban, the wildly successful entrepreneur and NBA owner, has committed himself to solving these two problems. Read the rest…

Drug Pricing 324

Drug Pricing 324

STAT

APRIL 10, 2024

In addition, the notable price hike also highlights a question about the extent to which penalties that are assessed by Medicaid and Medicare — which are levied for raising drug prices above inflation — are sometimes considered to be a cost of doing business. Continue to STAT+ to read the full story…

Drug Pricing 362

Drug Pricing 362

STAT

SEPTEMBER 10, 2024

This is Part 4 of “ Behind the Counter ,” an in-depth video series demystifying the complex world of patents and drug pricing. But in 1984, a little-known law put an end to that waiting period and paved the way for the large quantity of generic drugs available today.

Drug Pricing 301

Drug Pricing 301

STAT

SEPTEMBER 23, 2024

As the Hatch-Waxman Act approaches its 40th anniversary, it’s time to critically examine its legacy and what it actually gave us: the  highest drug prices in the world. One of the main objectives of the Hatch-Waxman Act was to bring more generic drugs into the market.

Drug Pricing 361

Drug Pricing 361

STAT

SEPTEMBER 17, 2024

filed a lawsuit on Tuesday demanding that a recent Federal Trade Commission report accusing industry middlemen of raising drug prices be vacated. Express Scripts, one of the largest pharmacy benefit managers in the U.S.,

Independent Pharmacies 360

Independent Pharmacies Drug Pricing 360

STAT

AUGUST 8, 2024

This is Part 3 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. Discovering a new drug is a big win for a pharmaceutical company, but selling it for lots of money with no competition? The cherry on top. Read the rest…

Drug Pricing 327

Drug Pricing Pharmaceutical Companies Pharmaceutical Companies 327

STAT

AUGUST 12, 2024

” A report from the House Committee on Oversight and Accountability issued on July 23, 2024, was almost as scathing, finding that PBMs “inflate prescription drug costs and interfere with patient care for their own financial benefit.” That view is wrong. Read the rest…

Drug Pricing 339

Drug Pricing 339

STAT

SEPTEMBER 26, 2023

Extending patent protection doesn’t just stretch a drug’s profits — in some cases, doing so can lead to its most significant revenue period, according to a recent analysis published by the Initiative for Medicines, Access & Knowledge, or I-MAK, a nonprofit advocating for drug pricing reforms.

Drug Pricing 357

Drug Pricing Biosimilars Drug Development 357

STAT

OCTOBER 18, 2024

Discounts from 340B are not publicly disclosed, but the Government Accountability Office estimated them at 20% to 50% of drug prices, and some estimates are even higher. Health care providers charge insurers full market prices for those drugs and keep the difference.

Drug Pricing 318

Drug Pricing Hospitals 318

STAT

AUGUST 16, 2024

  The Centers for Medicare & Medicaid Services released the Maximum Fair Prices (MFPs) for the first 10 drugs subject to negotiation under the Inflation Reduction Act. This is an important moment in prescription drug pricing policy.

Drug Pricing 285

Drug Pricing Diabetes 285

STAT

DECEMBER 5, 2023

At first blush, it sounds like the model popularized by Mark Cuban of Shark Tank fame, whose own drug program claims to save employers up to 60% compared with conventional arrangements.

Drug Pricing 363

Drug Pricing 363

STAT

MARCH 18, 2024

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

Biosimilars 363

Biosimilars Drug Pricing Documentation Pharmaceutical Companies 363

STAT

MAY 3, 2024

Generic injectables account for 67% of shortages, and more than half of drugs in short supply cost less than $1 per unit, according to the Finance Committee. Hospitals band together to negotiate drug prices by hiring group purchasing organizations. Finance Chair Ron Wyden (D-Ore.)

Hospitals 296

Hospitals Drug Pricing 296

STAT

JANUARY 25, 2024

has quietly built a conglomerate that deeply influences every part of health care, from insurance and drug pricing to primary care and home medical visits. But CVS has become much more than a pharmacy colossus. The company, based in Woonsocket, R.I.,

Drug Pricing 337

Drug Pricing 337

STAT

NOVEMBER 29, 2023

PBMs are companies that serve as the controversial middlemen of drug pricing negotiations, and of the four largest, two are owned by Cigna and Humana. A proposed transaction would almost certainly prompt a close review from antitrust enforcers at the Department of Justice and the Federal Trade Commission.

Drug Pricing 341

Drug Pricing 341

STAT

AUGUST 7, 2024

The polarized debate over drug pricing has generated cartoonish, sometimes colorful caricatures of the biopharmaceutical industry and its leaders. Critics of the industry have portrayed pharmaceutical leaders as ruthless, rapacious leaders who gouge patients to gratify greedy shareholders.

Drug Pricing 285

Drug Pricing 285

STAT

FEBRUARY 1, 2024

Biotech can’t shake the Fed The XBI, a closely watched index of biotech stocks, turned red for the year yesterday, and not because of a clinical disappointment, a drug pricing scandal, or an M&A rumor that came to nothing. In 2024, as in 2023, the industry’s fate seems inextricable from interest rates.

Drug Pricing 321

Drug Pricing Vaccines Communication Drug Development 321